August 14, 2006 – Neurochem got an Approvable letter for an Amyloid A amyloidosis drug; Gilead touted results of its HIV/AIDS medications; Teva launched a generic version of Zoloft; ViroPharma and Wyeth said data showed “proof of concept” for their hepatitis C compound; Schering-Plough and Novartis will combine two drugs for a new asthma medication; Abbott began a new trial of its Xience V drug eluting stent; MedImmune responded to FDA questions about its new inhaled flu vaccine; Centocor expanded the indication for arthritis drug Remicade; Aida Pharma now owns 77.5% of Shanghai Qiaer Bio-Tech; and Sanofi-Aventis and Bristol-Myers Squibb filed to prevent distribution of a generic version of Plavix. The Centient Biotech 200™ was almost flat, moving down less than 1 point to 3583.71, a loss of .02%. More details...
